The burden of extended-spectrum β-lactamase-producing Enterobacteriaceae in patients with cirrhosis

Hepatology International, Sep 2014

Richard Moreau

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

http://link.springer.com/content/pdf/10.1007%2Fs12072-014-9567-z.pdf

The burden of extended-spectrum β-lactamase-producing Enterobacteriaceae in patients with cirrhosis

Richard Moreau 0 1 2 3 0 R. Moreau Service d'Hepatologie, Departement Hospitalo-Universitaire (DHU) UNITY , Hopital Beaujon, AP-HP, Clichy, France 1 R. Moreau Faculte de Medecine, Universite Paris Diderot , Paris, France 2 R. Moreau (&) Inserm UMR_S 1149, Centre de Recherche sur l'Inflammation (CRI), Inserm et Universite Paris-Diderot , Paris 7 - Site Bichat, 16 Rue Henri Huchard, 75890 Paris Cedex 18, France 3 R. Moreau Laboratoire d'Excellence (Labex) Inflamex , PRES Sorbonne Paris Cite, Paris, France Patients with cirrhosis have high susceptibility to bacterial infections [1]; 24 % of patients admitted to the hospital for an acute decompensation of cirrhosis have bacterial infection [2]. The most common infection is spontaneous bacterial peritonitis (SBP) [1, 2]. It is well known that SBP is caused by Gram-negative bacteria such as Escherichia coli or Klebsiella pneumoniae originating from the intestinal lumen [3]. The translocation of intestinal bacteria is a crucial step in the process leading to SBP [1, 4]. Little is known about underlying mechanisms that explain bacterial translocation [4]. During the last 30 years the mortality of SBP has decreased from 70 to 30 % [3]. This was the result of large use of a strategy which includes high index of suspicion leading to diagnosis paracentesis, diagnosis of SBP based on neutrophil count C250/mL in the ascitic fluid and subsequent rapid initiation (before results of culture) of wide spectrum, non-nephrotoxic antibiotics (e.g., third generation cephalosporins) against Enterobacteriaceae (E. coli, K. pneumonia) which are the most common causes - of SBP [3]. In the late 1990s mortality of SBP was further decreased to 10 % with the combined use of empiric antibiotics and the intravenous administration of human albumin [5]. This beneficial effect was related to a significant decrease in the development of kidney failure (known as hepatorenal syndrome, HRS) [5]. Today, SBP remains the most common trigger of infection-induced acute-onchronic liver failure (ACLF) [2]. ACLF whichever its trigger, is characterized by the failure(s) of organs (including kidney, cerebral, liver, coagulation, circulation and lungs) and high risk of death depending on the number of failing organs [2]. Due to the severity of SBP, efforts have been made to prevent this complication. In patients who survive an episode of SBP long-term prophylaxis with the fluoroquinolone norfloxacin significantly decreases the risk of recurrent SBP [3]. The impact on survival is unknown. In patients with low ascitic fluid protein levels (\1.5 g/dL) but without a prior episode of SBP the efficacy of primary prophylaxis using a fuoroquinolone is still unclear. One trial has shown that norfloxacin significantly decreased the risk for developing a first episode of SBP [6], a finding that was not confirmed in another trial with ciprofloxacin [7]. Recently, an increasing number of cases of SBP due to extended spectrum b-lactamase (ESBL)-producing E. coli, K. pneumonia have been reported in Asia [811] and Europe [1216]. Some risk factors for SBP caused by ESBL-producing bacteria Enterobacteriaceae have been identified including the in-hospital acquisition of infection [1015], long-term norfloxacin prophylaxis [13], use of blactams within the last 3 months [13], and infection by multiresistant bacteria in the last 6 months [13]. ESBLproducing strains are resistant not only to third-generation cephalosporins, amoxicillin-clavulanic acid but also to quinolones and trimethoprim-sulfamethoxazole [13]. ESBL-producing strains are usually sensitive to carbapenems although some cases have reported of carbapenemaseproducing Enterobacteriacea [16]. In any case, these findings indicate that international recommendations stating that third-generation cephalosporins or amoxicillinclavulanic acid are the empiric antibiotics of choice for SBP [3] and are inappropriate for SBP episodes caused by ESBL-producing bacteria. Finally, studies have shown that SBP episodes due to ESBL-producing bacteria are more severe than episodes caused by strains sensitive to recommended empiric antibiotics [1014]. The reasons for the severity of infections due to ESBL-producing bacteria are unknown; theoretically, poor prognosis may be related to a greater severity of the underlying liver disease, higher prevalence of septic shock, or delayed initiation of appropriate antibiotics. In this issue of Hepatology International Kim et al. [17] report results of a retrospective analysis conducted in 231 patients with SBP due to E. coli or K. pneumonia of which 52 were caused by ESBL-producing strains. This study confirms that SBP caused by ESBL-producing strains are more severe than those due to other bacteria, whereby morality at day-7 and day-30 was 21.2 vs. 10.1 % (p = 0.03) and 34.6 vs. 18.4 % (p = 0.01), respectively. As expected [13], infections due to ESBL-producing bacteria were more frequently hospital-acquired. Interestingly, the severity o (...truncated)


This is a preview of a remote PDF: http://link.springer.com/content/pdf/10.1007%2Fs12072-014-9567-z.pdf

Richard Moreau. The burden of extended-spectrum β-lactamase-producing Enterobacteriaceae in patients with cirrhosis, Hepatology International, 2014, pp. 475-477, Volume 8, Issue 4, DOI: 10.1007/s12072-014-9567-z